APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-L1 Biomarker Testing

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.

PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.

Selected research

Market Outlook & Growth Opportunities

Global PD-L1 Biomarker Testing Market Outlook and Growth Opportunities 2026

31 December 2025199 pages

Choose your research edition.

Industry ResearchPD-L1 Biomarker Testing Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-L1 Biomarker Testing Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal PD-L1 Biomarker Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-L1 Biomarker Testing Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-L1 Biomarker Testing Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.

Read the full market overview

PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.

The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.

PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.

North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.

This report provides an overview of the global PD-L1 Biomarker Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PD-L1 Biomarker Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PD-L1 Biomarker Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global PD-L1 Biomarker Testing market.

PD-L1 Biomarker Testing Segment by Company

Agilent Technologies

Roche

Merck

Bristol-Myers Squibb

AstraZeneca

Ono Pharmaceutical

Regeneron

Innovent

Hengrui Medicine

Junshi Biosciences

PD-L1 Biomarker Testing Segment by Type

PD-L1 (22C3)

PD-L1(28-8)

PD-L1 (SP142)

PD-L1 (SP263)

Other

PD-L1 Biomarker Testing Segment by Application

Hospital

Diagnostic Center

Others

PD-L1 Biomarker Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global PD-L1 Biomarker Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the PD-L1 Biomarker Testing key companies, revenue, market share, and recent developments.

3. To split the PD-L1 Biomarker Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions PD-L1 Biomarker Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify PD-L1 Biomarker Testing significant trends, drivers, influence factors in global and regions.

6. To analyze PD-L1 Biomarker Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-L1 Biomarker Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-L1 Biomarker Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-L1 Biomarker Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PD-L1 Biomarker Testing industry.

Chapter 3: Detailed analysis of PD-L1 Biomarker Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of PD-L1 Biomarker Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of PD-L1 Biomarker Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. PD-L1 Biomarker Testing Industry Trends Table 2. PD-L1 Biomarker Testing Industry Drivers Table 3. PD-L1 Biomarker Testing Industry Opportunities and Challenges Table 4. PD-L1 Biomarker Testing Industry Restraints Table 5. Global PD-L1 Biomarker Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global PD-L1 Biomarker Testing Revenue Share by Company (2021-2026) Table 7. Global PD-L1 Biomarker Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global PD-L1 Biomarker Testing Key Company Manufacturing Base & Headquarters Table 9. Global PD-L1 Biomarker Testing Company, Product Type & Application Table 10. Global PD-L1 Biomarker Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global PD-L1 Biomarker Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of PD-L1 (22C3) Table 15. Significant Companies of PD-L1(28-8) Table 16. Significant Companies of PD-L1 (SP142) Table 17. Significant Companies of PD-L1 (SP263) Table 18. Significant Companies of Other Table 19. Global PD-L1 Biomarker Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global PD-L1 Biomarker Testing Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global PD-L1 Biomarker Testing Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global PD-L1 Biomarker Testing Sales Value Share by Type (2021-2026) Table 23. Global PD-L1 Biomarker Testing Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Table 25. Significant Companies of Diagnostic Center Table 26. Significant Companies of Others Table 27. Global PD-L1 Biomarker Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global PD-L1 Biomarker Testing Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global PD-L1 Biomarker Testing Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global PD-L1 Biomarker Testing Sales Value Share by Application (2021-2026) Table 31. Global PD-L1 Biomarker Testing Sales Value Share by Application (2027-2032) Table 32. Global PD-L1 Biomarker Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global PD-L1 Biomarker Testing Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global PD-L1 Biomarker Testing Sales Value Share by Region (2021-2026) Table 35. Global PD-L1 Biomarker Testing Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global PD-L1 Biomarker Testing Sales Value Share by Region (2027-2032) Table 37. Global PD-L1 Biomarker Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global PD-L1 Biomarker Testing Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global PD-L1 Biomarker Testing Sales Value Market Share by Country (2021-2026) Table 40. Global PD-L1 Biomarker Testing Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global PD-L1 Biomarker Testing Sales Value Market Share by Country (2027-2032) Table 42. Agilent Technologies Company Information Table 43. Agilent Technologies Business Overview Table 44. Agilent Technologies PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Agilent Technologies PD-L1 Biomarker Testing Product Portfolio Table 46. Agilent Technologies Recent Development Table 47. Roche Company Information Table 48. Roche Business Overview Table 49. Roche PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Roche PD-L1 Biomarker Testing Product Portfolio Table 51. Roche Recent Development Table 52. Merck Company Information Table 53. Merck Business Overview Table 54. Merck PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Merck PD-L1 Biomarker Testing Product Portfolio Table 56. Merck Recent Development Table 57. Bristol-Myers Squibb Company Information Table 58. Bristol-Myers Squibb Business Overview Table 59. Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Bristol-Myers Squibb PD-L1 Biomarker Testing Product Portfolio Table 61. Bristol-Myers Squibb Recent Development Table 62. AstraZeneca Company Information Table 63. AstraZeneca Business Overview Table 64. AstraZeneca PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. AstraZeneca PD-L1 Biomarker Testing Product Portfolio Table 66. AstraZeneca Recent Development Table 67. Ono Pharmaceutical Company Information Table 68. Ono Pharmaceutical Business Overview Table 69. Ono Pharmaceutical PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Ono Pharmaceutical PD-L1 Biomarker Testing Product Portfolio Table 71. Ono Pharmaceutical Recent Development Table 72. Regeneron Company Information Table 73. Regeneron Business Overview Table 74. Regeneron PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Regeneron PD-L1 Biomarker Testing Product Portfolio Table 76. Regeneron Recent Development Table 77. Innovent Company Information Table 78. Innovent Business Overview Table 79. Innovent PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Innovent PD-L1 Biomarker Testing Product Portfolio Table 81. Innovent Recent Development Table 82. Hengrui Medicine Company Information Table 83. Hengrui Medicine Business Overview Table 84. Hengrui Medicine PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Hengrui Medicine PD-L1 Biomarker Testing Product Portfolio Table 86. Hengrui Medicine Recent Development Table 87. Junshi Biosciences Company Information Table 88. Junshi Biosciences Business Overview Table 89. Junshi Biosciences PD-L1 Biomarker Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Junshi Biosciences PD-L1 Biomarker Testing Product Portfolio Table 91. Junshi Biosciences Recent Development Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. PD-L1 Biomarker Testing Product Image Figure 2. Global PD-L1 Biomarker Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global PD-L1 Biomarker Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. PD-L1 (22C3) Image Figure 8. PD-L1(28-8) Image Figure 9. PD-L1 (SP142) Image Figure 10. PD-L1 (SP263) Image Figure 11. Other Image Figure 12. Global PD-L1 Biomarker Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global PD-L1 Biomarker Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global PD-L1 Biomarker Testing Sales Value Share by Type (2021-2032) Figure 15. Hospital Image Figure 16. Diagnostic Center Image Figure 17. Others Image Figure 18. Global PD-L1 Biomarker Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global PD-L1 Biomarker Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global PD-L1 Biomarker Testing Sales Value Share by Application (2021-2032) Figure 21. Global PD-L1 Biomarker Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global PD-L1 Biomarker Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America PD-L1 Biomarker Testing Sales Value (2021-2032) & (US$ Million) Figure 24. North America PD-L1 Biomarker Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe PD-L1 Biomarker Testing Sales Value (2021-2032) & (US$ Million) Figure 26. Europe PD-L1 Biomarker Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific PD-L1 Biomarker Testing Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific PD-L1 Biomarker Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America PD-L1 Biomarker Testing Sales Value (2021-2032) & (US$ Million) Figure 30. South America PD-L1 Biomarker Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa PD-L1 Biomarker Testing Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa PD-L1 Biomarker Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • PD-L1 (22C3)
  • PD-L1(28-8)
  • PD-L1 (SP142)
  • PD-L1 (SP263)
  • Other
Applications
  • Hospital
  • Diagnostic Center
  • Others
Companies covered
  • Agilent Technologies
  • Roche
  • Merck
  • Bristol-Myers Squibb
  • AstraZeneca
  • Ono Pharmaceutical
  • Regeneron
  • Innovent
  • Hengrui Medicine
  • Junshi Biosciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PD-L1 Biomarker Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PD-L1 Biomarker Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 PD-L1 Biomarker Testing Market Dynamics
  1. 2.1 PD-L1 Biomarker Testing Industry Trends
  2. 2.2 PD-L1 Biomarker Testing Industry Drivers
  3. 2.3 PD-L1 Biomarker Testing Industry Opportunities and Challenges
  4. 2.4 PD-L1 Biomarker Testing Industry Restraints
3 PD-L1 Biomarker Testing Market by Company
  1. 3.1 Global PD-L1 Biomarker Testing Company Revenue Ranking in 2025
  2. 3.2 Global PD-L1 Biomarker Testing Revenue by Company (2021-2026)
  3. 3.3 Global PD-L1 Biomarker Testing Company Ranking (2024-2026)
  4. 3.4 Global PD-L1 Biomarker Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global PD-L1 Biomarker Testing Company Product Type and Application
  6. 3.6 Global PD-L1 Biomarker Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global PD-L1 Biomarker Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 PD-L1 Biomarker Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 PD-L1 Biomarker Testing Market by Type
  1. 4.1 PD-L1 Biomarker Testing Type Introduction
  2. 4.1.1 PD-L1 (22C3)
  3. 4.1.2 PD-L1(28-8)
  4. 4.1.3 PD-L1 (SP142)
  5. 4.1.4 PD-L1 (SP263)
  6. 4.1.5 Other
  7. 4.2 Global PD-L1 Biomarker Testing Sales Value by Type
  8. 4.2.1 Global PD-L1 Biomarker Testing Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global PD-L1 Biomarker Testing Sales Value by Type (2021-2032)
  10. 4.2.3 Global PD-L1 Biomarker Testing Sales Value Share by Type (2021-2032)
5 PD-L1 Biomarker Testing Market by Application
  1. 5.1 PD-L1 Biomarker Testing Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Diagnostic Center
  4. 5.1.3 Others
  5. 5.2 Global PD-L1 Biomarker Testing Sales Value by Application
  6. 5.2.1 Global PD-L1 Biomarker Testing Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PD-L1 Biomarker Testing Sales Value by Application (2021-2032)
  8. 5.2.3 Global PD-L1 Biomarker Testing Sales Value Share by Application (2021-2032)
6 PD-L1 Biomarker Testing Regional Value Analysis
  1. 6.1 Global PD-L1 Biomarker Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PD-L1 Biomarker Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global PD-L1 Biomarker Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global PD-L1 Biomarker Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PD-L1 Biomarker Testing Sales Value (2021-2032)
  7. 6.3.2 North America PD-L1 Biomarker Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe PD-L1 Biomarker Testing Sales Value (2021-2032)
  10. 6.4.2 Europe PD-L1 Biomarker Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific PD-L1 Biomarker Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific PD-L1 Biomarker Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America PD-L1 Biomarker Testing Sales Value (2021-2032)
  16. 6.6.2 South America PD-L1 Biomarker Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa PD-L1 Biomarker Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa PD-L1 Biomarker Testing Sales Value Share by Country, 2025 VS 2032
7 PD-L1 Biomarker Testing Country-level Value Analysis
  1. 7.1 Global PD-L1 Biomarker Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global PD-L1 Biomarker Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global PD-L1 Biomarker Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global PD-L1 Biomarker Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt PD-L1 Biomarker Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt PD-L1 Biomarker Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt PD-L1 Biomarker Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Agilent Technologies
  2. 8.1.1 Agilent Technologies Company Information
  3. 8.1.2 Agilent Technologies Business Overview
  4. 8.1.3 Agilent Technologies PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Agilent Technologies PD-L1 Biomarker Testing Product Portfolio
  6. 8.1.5 Agilent Technologies Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Roche PD-L1 Biomarker Testing Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck PD-L1 Biomarker Testing Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb PD-L1 Biomarker Testing Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca PD-L1 Biomarker Testing Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Ono Pharmaceutical
  32. 8.6.1 Ono Pharmaceutical Company Information
  33. 8.6.2 Ono Pharmaceutical Business Overview
  34. 8.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ono Pharmaceutical PD-L1 Biomarker Testing Product Portfolio
  36. 8.6.5 Ono Pharmaceutical Recent Developments
  37. 8.7 Regeneron
  38. 8.7.1 Regeneron Company Information
  39. 8.7.2 Regeneron Business Overview
  40. 8.7.3 Regeneron PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Regeneron PD-L1 Biomarker Testing Product Portfolio
  42. 8.7.5 Regeneron Recent Developments
  43. 8.8 Innovent
  44. 8.8.1 Innovent Company Information
  45. 8.8.2 Innovent Business Overview
  46. 8.8.3 Innovent PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Innovent PD-L1 Biomarker Testing Product Portfolio
  48. 8.8.5 Innovent Recent Developments
  49. 8.9 Hengrui Medicine
  50. 8.9.1 Hengrui Medicine Company Information
  51. 8.9.2 Hengrui Medicine Business Overview
  52. 8.9.3 Hengrui Medicine PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hengrui Medicine PD-L1 Biomarker Testing Product Portfolio
  54. 8.9.5 Hengrui Medicine Recent Developments
  55. 8.10 Junshi Biosciences
  56. 8.10.1 Junshi Biosciences Company Information
  57. 8.10.2 Junshi Biosciences Business Overview
  58. 8.10.3 Junshi Biosciences PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Junshi Biosciences PD-L1 Biomarker Testing Product Portfolio
  60. 8.10.5 Junshi Biosciences Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst